Aspireo Receives Positive Opinion from EMA for Orphan Disease Designation for Somatoprim

News   Nov 26, 2012

 
Aspireo Receives Positive Opinion from EMA for Orphan Disease Designation for Somatoprim
 
 
 

RELATED ARTICLES

XenoGesis and Juniper Pharma Services Strengthen Alliance

News

Campanies extend strategic alliance in early drug development services.

READ MORE

Quotient Clinical Signs Cocrystal Agreement with Nuformix

News

Partnership to evaluate cocrystal formulations using translational pharmaceutics.

READ MORE

Battling Flames Increases Firefighters’ Exposure to Carcinogens

News

Researchers have measured how much firefighters' exposure to carcinogens and other harmful compounds increases when fighting fires.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE